New Supply Agreement Between AtomVie Global Radiopharma and ITM Enhances Access to Lutetium-177

AtomVie Global Radiopharma and ITM Join Forces for Lutetium-177 Supply



In a significant development within the radiopharmaceutical landscape, AtomVie Global Radiopharma and ITM Isotope Technologies Munich SE have formalized a supply agreement aimed at providing high-quality non-carrier-added Lutetium-177 (n.c.a. 177Lu). This partnership promises to bolster AtomVie’s contract development and manufacturing operations, thereby enhancing the availability of this critical radioisotope for precision oncology.

Bruno Paquin, CEO of AtomVie, highlighted the importance of reliable supply chains in the radiopharmaceutical sector. He stated, “AtomVie serves a diverse array of radiopharmaceutical companies that depend on consistent access to high-quality radioisotopes. By strengthening our partnership with ITM, we ensure our current and future partners benefit from dependable access to n.c.a. 177Lu, supporting their therapeutic and diagnostic innovations.”

ITM's n.c.a. 177Lu serves a vital role in targeted cancer therapies. By attaching this radioisotope to specific targeting molecules, it can directly deliver therapeutic beta radiation to tumor sites, maximizing the destruction of cancer cells with precision and minimal impact on surrounding healthy tissue. Notably, ITM holds a U.S. Drug Master File with the FDA for n.c.a. 177Lu, alongside marketing authorization in the EU under the brand name EndolucinBeta®.

Dr. Andrew Cavey, CEO of ITM, expressed pride in the collaboration, noting that it exemplifies their commitment to serve the radiopharmaceutical industry through a robust production and supply network. “Ensuring our partners have reliable access to high-quality radioisotopes like Lutetium-177 is a priority for us. Together with AtomVie and its network, we aim to expand the impact of radiopharmaceutical therapies for cancer patients,” he remarked.

This strategic agreement comes at a time when the demand for advanced cancer therapies is on the rise. The partnership is poised to facilitate innovative therapeutic and diagnostic developments, supporting a wide range of oncology programs worldwide.

About AtomVie Global Radiopharma


AtomVie Global Radiopharma Inc. stands as a premier contract development and manufacturing organization dedicated to the advancement of radiopharmaceuticals. Their comprehensive services include process and analytical method development, GMP manufacturing, quality control, regulatory support, and global distribution, all aimed at facilitating the clinical and commercial launch of drug products.

With a commitment to support pharmaceutical and biotechnology companies in their quest for developing innovative radiotherapeutics and diagnostics, AtomVie is currently commissioning a state-of-the-art facility in Hamilton, Ontario, further enhancing its capacity to meet growing industry needs.

For more information about AtomVie, visit www.atomvie.com.

About ITM Isotope Technologies Munich SE


ITM is a leading player in the biotechnology landscape, focused on providing advanced radiopharmaceutical therapeutics and diagnostics specifically for challenging tumors. Their mission centers around delivering enhanced patient outcomes through exceptional development, production, and global supply of medical radioisotopes.

By advancing a comprehensive pipeline of precision oncology solutions, ITM leverages over two decades of expertise in radiopharmaceuticals to improve treatment effectiveness and quality of life for cancer patients.

For more information about ITM, visit www.itm-radiopharma.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.